CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine

Raphaelle Fanciullino (1) , Laure Farnault (2) , Mélanie Donnette (1) , Diane-Charlotte Imbs (1) , Catherine Roche (3) , Geoffroy Venton (2) , Yael Berda-Haddad (3) , Vadim Ivanov (3) , Joseph Ciccolini (1, 3) , L’houcine Ouafik (4, 5) , Bruno Lacarelle (1, 3) , Régis Costello (2)

1 SMARTc unit - Simulation & Modelling : Adaptive Response for Therapeutics in Cancer
2 Service d’hématologie et de thérapie cellulaire
3 APHM - Assistance Publique - Hôpitaux de Marseille
4 CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie
5 Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM]

Key Points Ara-C is the mainstay of treatment for patients with AML, and life-threatening toxicities are common. We demonstrated that cytidine deaminase downregulation predicts severe/lethal toxicities with cytarabine.

Domaines: Cancer

Raphaelle Fanciullino, Laure Farnault, Mélanie Donnette, Diane-Charlotte Imbs, Catherine Roche, et al.. CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Advances, 2018, 2 (5), pp.462 - 469. ⟨10.1182/bloodadvances.2017014126⟩. ⟨hal-01770057⟩